口服抗凝药相关脑出血住院患者的临床特征与结局
该队列研究纳入2013年10月至2018年5月美国1870家医院Get With The Guidelines-Stroke登记的非创伤性ICH患者219701例,其中4.2%服FXa抑制剂、9.8%服华法林、86.0%未服口服抗凝药。与未抗凝者相比,FXa抑制剂(aOR 1.27;95%CI 1.20-1.34)和华法林(aOR 1.67;95%CI 1.60-1.74)均与更高的院内死亡风险相关。FXa抑制剂患者死亡或出院转临终关怀的风险也高于未抗凝者(aOR 1.19;95%CI 1.13-1.26),但低于华法林患者(aOR 0.79;95%CI 0.75-0.84)。华法林联合抗血小板治疗较单用华法林结局更差,而FXa抑制剂联合抗血小板未见显著额外风险。
要点
- FXa抑制剂相关ICH患者院内死亡27.0%(2487/9202),高于未抗凝者22.6%(42660/189069),aOR 1.27(95%CI 1.20-1.34)。
- 华法林相关ICH患者院内死亡32.8%(7032/21430),高于未抗凝者,aOR 1.67(95%CI 1.60-1.74)。
- FXa抑制剂患者较华法林患者院内死亡风险更低(aOR 0.76;95%CI 0.72-0.81),死亡或转临终关怀风险也更低(aOR 0.79;95%CI 0.75-0.84)。
- 华法林联合双联抗血小板治疗较单用华法林院内死亡风险更高(aOR 2.07;95%CI 1.72-2.50),FXa抑制剂联合抗血小板未见显著额外风险。
适用人群与场景
- 2013年10月至2018年5月入住美国1870家医院的219701例非创伤性ICH患者(平均年龄68.2岁,女性47.8%)。
- 按ICH前口服抗凝情况分为FXa抑制剂组9202例(4.2%)、华法林组21430例(9.8%)和未抗凝组189069例(86.0%)。
- FXa抑制剂或华法林组患者年龄更大、心血管危险因素患病率更高。
研究设计与关键结果
- 研究类型:队列研究,基于Get With The Guidelines-Stroke登记,纳入219701例非创伤性ICH患者,分布于1870家医院。
- 主要终点院内死亡:FXa抑制剂组27.0%(2487/9202)vs 未抗凝组22.6%(42660/189069),aOR 1.27(95%CI 1.20-1.34;P<.001);华法林组32.8%(7032/21430)vs 未抗凝组,aOR 1.67(95%CI 1.60-1.74;P<.001)。
- 次要终点死亡或出院转临终关怀:FXa抑制剂组37.8%(3478/9202)vs 未抗凝组30.7%(58022/189069),aOR 1.19(95%CI 1.13-1.26;P<.001);华法林组42.7%(9151/21430)vs 未抗凝组,aOR 1.50(95%CI 1.44-1.56;P<.001)。
- FXa抑制剂组较华法林组院内死亡aOR 0.76(95%CI 0.72-0.81;P<.001),死亡或转临终关怀aOR 0.79(95%CI 0.75-0.84;P<.001),出院回家aOR 1.18(95%CI 1.10-1.26;P<.001),出院mRS 0-1分aOR 1.24(95%CI 1.09-1.40;P<.001)。
- FXa抑制剂组出院回家、独立行走、mRS 0-1分及mRS 0-2分率数值上低于未抗凝组,但差异无统计学显著性。
- 华法林联合双联抗血小板较单用华法林院内死亡aOR 2.07(95%CI 1.72-2.50;P<.001);FXa抑制剂联合抗血小板的额外风险无统计学显著性。
证据类型、等级与局限
- 证据类型:基于注册登记的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于非创伤性ICH患者,入院时需明确ICH前是否服用FXa抑制剂或华法林,因其与院内死亡风险升高相关(FXa抑制剂aOR 1.27,华法林aOR 1.67)。
- FXa抑制剂相关ICH患者的院内死亡及死亡/转临终关怀风险低于华法林相关ICH患者(aOR 0.76和0.79),但出院回家、独立行走及mRS 0-1/0-2分率与未抗凝者的差异无统计学显著性。
- 华法林联合抗血小板治疗(单联或双联)较单用华法林结局更差(双联抗血小板院内死亡aOR 2.07),FXa抑制剂联合抗血小板未见显著额外风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Although the use of factor Xa (FXa) inhibitors has increased substantially over the past decade, there are limited data on characteristics and outcomes of FXa inhibitor-associated intracerebral hemorrhage (ICH).
OBJECTIVE: To investigate the association between prior oral anticoagulant use (FXa inhibitors, warfarin, or none) and in-hospital outcomes among patients with nontraumatic ICH.
DESIGN, SETTING, AND PARTICIPANTS: This is a cohort study of 219 701 patients with nontraumatic ICH admitted to 1870 hospitals in the Get With The Guidelines-Stroke registry between October 2013 and May 2018. Data analysis was performed in December 2019.
EXPOSURES: Anticoagulation therapy before ICH.
MAIN OUTCOMES AND MEASURES: The primary outcome was in-hospital mortality. Secondary outcomes were a composite measure of in-hospital mortality or discharge to hospice, discharge home, independent ambulation, and modified Rankin Scale (mRS) score at discharge.
RESULTS: Of 219 701 patients (mean [SD] age, 68.2 [15.3] years; 104 940 women [47.8%]), 9202 (4.2%) were taking FXa inhibitors, 21 430 (9.8%) were taking warfarin, and 189 069 (86.0%) were not taking any oral anticoagulant before ICH. Patients taking FXa inhibitors or warfarin were older and had higher prevalence of cardiovascular risk factors. Compared with those not taking an oral anticoagulant (42 660 of 189 069 patients [22.6%]), the in-hospital mortality risk was higher for both FXa inhibitors (2487 of 9202 patients [27.0%]; adjusted odds ratio [aOR], 1.27; 95% CI, 1.20-1.34; P < .001) and warfarin (7032 of 21 430 patients [32.8%]; aOR, 1.67; 95% CI, 1.60-1.74; P < .001). Both FXa inhibitors (3478 of 9202 patients [37.8%]; aOR, 1.19; 95% CI, 1.13-1.26; P < .001) and warfarin (9151 of 21 430 patients [42.7%]; aOR, 1.50; 95% CI, 1.44-1.56; P < .001) were associated with higher odds of death or discharge to hospice compared with not taking oral anticoagulation (58 022 of 189 069 patients [30.7%]). Although the rates of discharge home, independent ambulation, mRS scores of 0 or 1, and mRS scores of 0 to 2 were numerically lower among patients taking FXa inhibitors, these differences were not significant compared with patients not taking oral anticoagulants. In contrast, patients taking FXa inhibitors were less likely to die (aOR, 0.76; 95% CI, 0.72-0.81; P < .001) or to experience death or discharge to hospice (aOR, 0.79; 95% CI, 0.75-0.84; P < .001), more likely to be discharged home (aOR, 1.18; 95% CI, 1.10-1.26; P < .001), and had better mRS scores at discharge (eg, mRS scores of 0-1: aOR, 1.24; 95% CI, 1.09-1.40; P < .001) than those treated with warfarin. Concomitant warfarin and antiplatelet therapy (either single or dual) was associated with worse outcomes compared with taking warfarin alone (eg, in-hospital mortality for dual-antiplatelet agents: aOR, 2.07; 95% CI, 1.72-2.50; P < .001). However, such incremental risk was not significant in patients taking FXa inhibitors.
CONCLUSIONS AND RELEVANCE: In this cohort study, FXa inhibitor-associated ICH was associated with higher risk of mortality or death or discharge to hospice than not taking an oral anticoagulant, but patients taking FXa inhibitors had better outcomes than those with warfarin-related ICH.
参考来源
- Xian Y, Zhang S, Inohara T, et al. Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage. JAMA Netw Open. 2021. PMID: 33591368. doi:10.1001/jamanetworkopen.2020.37438
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。